“It is anticipated that the first batches of a COVID-19 vaccine could be available for emergency use authorization in early 2021,” Mr. Stoffels told BusinessWorld in an e-mail response.
“We will continue to work with local and international health authorities, governments, regulators and NGOs (non-government organizations) to ensure that if development is successful and products approved, we achieve broad and timely access to our healthcare solutions,” he added.
The company is targeting to provide a global supply of more than one billion vaccine doses and expand global manufacturing capacity by establishing new manufacturing capacity in the United States, Europe, and/or Asia.